Department of Neurology, Division of Cerebrovascular Diseases, Beth Israel Deaconess Medical Center, 330 Brookline Avenue-Palmer 127, Boston, MA, 02215, USA,
Transl Stroke Res. 2010 Mar;1(1):35-9. doi: 10.1007/s12975-009-0001-0. Epub 2009 Dec 10.
The iron chelator, deferoxamine mesylate (DFO), has shown neuroprotective effects, mediated via suppression of iron-induced hydroxyl radical formation, in various animal models of ischemic and hemorrhagic stroke. Therefore, the objective of this study was to investigate whether DFO can exert similar actions in stroke patients, by examining the effects of treatment with DFO on biological markers of oxidative stress, namely serum total hydroperoxides and lipoperoxides and total radical trapping antioxidant capacity (TRAP), in stroke patients. We found that serum levels of peroxides were reduced, and TRAP levels increased after a 3-day treatment with DFO (500 mg). These findings provide a preliminary proof of concept that DFO can exert potential antioxidant neuroprotective effects in stroke patients. Future, larger-scale, randomized, and controlled studies to further evaluate the safety and efficacy of DFO in patients with stroke are warranted.
铁螯合剂甲磺酸去铁胺（DFO）在各种缺血性和出血性中风的动物模型中通过抑制铁诱导的羟自由基形成显示出神经保护作用。因此，本研究的目的是通过检查 DFO 治疗对氧化应激生物标志物（即血清总过氧化物和脂质过氧化物以及总自由基捕获抗氧化能力（TRAP））的影响，来研究 DFO 是否可以在中风患者中发挥类似作用。我们发现，DFO（500mg）治疗 3 天后，血清过氧化物水平降低，TRAP 水平升高。这些发现初步证明 DFO 可在中风患者中发挥潜在的抗氧化神经保护作用。未来需要更大规模、随机和对照研究来进一步评估 DFO 在中风患者中的安全性和疗效。
